Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Nephrotoxic effects of designer drugs: synthetic is not better!

Key Points

  • Designer drugs are synthesized to produce effects similar to scheduled or controlled chemical compounds

  • These drugs are used as 'legal highs' and are undetectable by standard toxicology tests

  • Designer drugs classified as amphetamine derivatives, phenylpiperazine derivatives, synthetic cathinones, synthetic cannabinoids, phencyclidine derivatives and synthetic opioids are increasingly being used as recreational drugs

  • When used excessively and/or when contaminated with toxic substances, designer drugs are associated with adverse renal effects

  • Acute kidney injury and hyponatraemia can result from the use of designer drugs

  • Clinicians should be aware of the toxicological profile of designer drugs and the potential for adverse renal effects

Abstract

Designer drugs are synthetic, psychoactive substances with similar structures and activity to existing scheduled drugs or controlled chemical compounds. The use of these drugs is not generally considered illegal and they cannot be detected using standard toxicology tests—essentially they are considered to be 'legal highs'. Over the past several years, increasing numbers of designer drugs have become available. These drugs are classified as amphetamine derivatives, phenylpiperazine derivatives, synthetic cathinones, synthetic cannabinoids, phencyclidine derivatives and synthetic opioids. Although euphoria is the desired effect, neuropsychiatric and cardiac manifestations are frequently observed in individuals using these drugs at high doses or using drugs that are contaminated with other substances. Some designer drugs are also associated with adverse renal effects, including acute kidney injury from pigment nephropathy, acute tubular necrosis, obstructive nephropathy and hyponatraemia. The misuse of these drugs should be recognized and clinicians made aware of the potential for acute nephrotoxicity as the health burden of these compounds increases.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: New designer drugs.
Figure 2: Prevalence of illicit drug use among high school students (aged 17–18 years) in the USA.
Figure 3: Acute kidney injury and various forms of nephrotoxicity associated with the use of designer drugs.
Figure 4: Examples of designer drugs.

References

  1. 1

    Freye, E. Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs (Springer, 2009).

    Google Scholar 

  2. 2

    German, C. L., Fleckenstein, A. E. & Hanson, G. R. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 97, 2–8 (2013).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  3. 3

    Davis, G. G. Drug abuse: newly-emerging drugs and trends. Clin. Lab. Med. 32, 407–414 (2012).

    Article  PubMed  Google Scholar 

  4. 4

    Carroll, F. I., Lewin, A. H., Mascarella, S. W., Seltzman, H. H. & Reddy, P. A. Designer drugs: a medicinal chemistry perspective. Ann. N. Y. Acad. Sci. 1248, 18–38 (2012).

    Article  CAS  PubMed  Google Scholar 

  5. 5

    [No authors listed] Legal highs and lows—illicit drug use around the world. Lancet 382, 1 (2013).

  6. 6

    Arnold, C. The new danger of synthetic drugs. Lancet 382, 15–16 (2013).

    Article  PubMed  Google Scholar 

  7. 7

    Bilinski, P., Kapka-Skrzypczak, L. & Jablonski, P. Determining the scale of designer drugs (DD) abuse and risk to public health in Poland through an epidemiological study in adolescents. Ann. Agric. Environ. Med. 19, 357–364 (2012).

    PubMed  Google Scholar 

  8. 8

    Albertson, T. E. Recreational drugs of abuse. Clin. Rev. Allergy Immunol. 46, 1–2 (2013).

    Article  CAS  Google Scholar 

  9. 9

    Schep, L. J., Slaughter, R. J. & Beasley, D. M. The clinical toxicology of metamfetamine. Clin. Toxicol. (Phila.) 48, 675–694 (2010).

    Article  CAS  Google Scholar 

  10. 10

    Lemere, F. The danger of amphetamine dependency. Am. J. Psychiatry 123, 569–572 (1966).

    Article  CAS  PubMed  Google Scholar 

  11. 11

    United Nations Office on Drugs and Crime. World Drug Report 2013. www.unodc.org[online], (2013).

  12. 12

    Winslow, B. T., Voorhees, K. I. & Pehl, K. A. Methamphetamine abuse. Am. Fam. Physician 76, 1169–1174 (2007).

    PubMed  Google Scholar 

  13. 13

    Ago, M., Ago, K., Hara, K., Kashimura, S. & Ogata, M. Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: a case report. Leg. Med. (Tokyo) 8, 235–239 (2006).

    Article  CAS  Google Scholar 

  14. 14

    Chan, P., Chen, J. H., Lee, M. H. & Deng, J. F. Fatal and nonfatal methamphetamine intoxication in the intensive care unit. J. Toxicol. Clin. Toxicol. 32, 147–155 (1994).

    Article  CAS  PubMed  Google Scholar 

  15. 15

    Molina, N. M. & Jejurikar, S. G. Toxicological findings in a fatal ingestion of methamphetamine. J. Anal. Toxicol. 23, 67–68 (1999).

    Article  CAS  PubMed  Google Scholar 

  16. 16

    Richards, J. R., Johnson, E. B., Stark, R. W. & Derlet, R. W. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am. J. Emerg. Med. 17, 681–685 (1999).

    Article  CAS  PubMed  Google Scholar 

  17. 17

    Citron, B. P. et al. Necrotizing angiitis associated with drug abuse. N. Engl. J. Med. 283, 1003–1011 (1970).

    Article  CAS  PubMed  Google Scholar 

  18. 18

    Shulgin, A. T. The background and chemistry of MDMA. J. Psychoactive Drugs 18, 291–304 (1986).

    Article  CAS  PubMed  Google Scholar 

  19. 19

    Kalant, H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ 165, 917–928 (2001).

    PubMed  PubMed Central  CAS  Google Scholar 

  20. 20

    Campbell, G. A. & Rosner, M. H. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin. J. Am. Soc. Nephrol. 3, 1852–1860 (2008).

    Article  CAS  PubMed  Google Scholar 

  21. 21

    Mas, M. et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J. Pharmacol. Exp. Ther. 290, 136–145 (1999).

    CAS  PubMed  Google Scholar 

  22. 22

    Maurer, H. H., Bickeboeller-Friedrich, J., Kraemer, T. & Peters, F. T. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('ecstasy'). Toxicol. Lett. 112–113, 133–142 (2000).

    Article  PubMed  Google Scholar 

  23. 23

    Wu, D., Otton, S. V., Inaba, T., Kalow, W. & Sellers, E. M. Interactions of amphetamine analogs with human liver CYP2D6. Biochem. Pharmacol. 53, 1605–1612 (1997).

    Article  CAS  PubMed  Google Scholar 

  24. 24

    de la Torre, R. et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 26, 137–144 (2004).

    Article  CAS  PubMed  Google Scholar 

  25. 25

    Demirkiran, M., Jankovic, J. & Dean, J. M. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin. Neuropharmacol. 19, 157–164 (1996).

    Article  CAS  PubMed  Google Scholar 

  26. 26

    Screaton, G. R. et al. Hyperpyrexia and rhabdomyolysis after MDMA (“ecstasy”) abuse. Lancet 339, 677–678 (1992).

    Article  CAS  PubMed  Google Scholar 

  27. 27

    Chadwick, I. S., Curry, P. D., Linsley, A., Freemont, A. J. & Doran, B. Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J. R. Soc. Med. 84, 371 (1991).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  28. 28

    van Dijken, G. D., Blom, R. E., Hene, R. J. & Boer, W. H. High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol. Dial. Transplant. 28, 2277–2283 (2013).

    Article  CAS  PubMed  Google Scholar 

  29. 29

    Ajaelo, I., Koenig, K. & Snoey, E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad. Emerg. Med. 5, 839–840 (1998).

    Article  CAS  PubMed  Google Scholar 

  30. 30

    Holden, R. & Jackson, M. A. Near-fatal hyponatraemic coma due to vasopressin over-secretion after “ecstasy” (3,4-MDMA). Lancet 347, 1052 (1996).

    Article  CAS  PubMed  Google Scholar 

  31. 31

    Budisavljevic, M. N., Stewart, L., Sahn, S. A. & Ploth, D. W. Hyponatremia associated with 3,4-methylenedioxymethylamphetamine (“ecstasy”) abuse. Am. J. Med. Sci. 326, 89–93 (2003).

    Article  PubMed  Google Scholar 

  32. 32

    Kalantar-Zadeh, K., Nguyen, M. K., Chang, R. & Kurtz, I. Fatal hyponatremia in a young woman after ecstasy ingestion. Nat. Clin. Pract. Nephrol. 2, 283–288 (2006).

    Article  PubMed  Google Scholar 

  33. 33

    Hartung, T. K., Schofield, E., Short, A. I., Parr, M. J. & Henry, J. A. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. Q. J. Med. 95, 431–437 (2002).

    Article  CAS  Google Scholar 

  34. 34

    Henry, J. A. et al. Low-dose MDMA (“ecstasy”) induces vasopressin secretion. Lancet 351, 1784 (1998).

    Article  CAS  PubMed  Google Scholar 

  35. 35

    Fallon, J. K. et al. Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann. N. Y. Acad. Sci. 965, 399–409 (2002).

    Article  CAS  PubMed  Google Scholar 

  36. 36

    Forsling, M. et al. Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (“ecstasy”): is metabolism a contributory factor? J. Pharm. Pharmacol. 53, 1357–1363 (2001).

    Article  CAS  PubMed  Google Scholar 

  37. 37

    Cherney, D. Z., Davids, M. R. & Halperin, M. L. Acute hyponatraemia and 'ecstasy': insights from a quantitative and integrative analysis. Q. J. Med. 95, 475–483 (2002).

    Article  CAS  Google Scholar 

  38. 38

    Hall, A. P. & Henry, J. A. Acute toxic effects of 'ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br. J. Anaesth. 96, 678–685 (2006).

    Article  CAS  PubMed  Google Scholar 

  39. 39

    Fahal, I. H., Sallomi, D. F., Yaqoob, M. & Bell, G. M. Acute renal failure after ecstasy. BMJ 305, 29 (1992).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  40. 40

    Siegel, R. K. MDMA. Nonmedical use and intoxication. J. Psychoactive Drugs 18, 349–354 (1986).

    Article  CAS  PubMed  Google Scholar 

  41. 41

    Hall, A. P. Dantrolene and “ecstasy”. Med. J. Aust. 167, 506–507 (1997).

    Article  CAS  PubMed  Google Scholar 

  42. 42

    Denborough, M. A. & Hopkinson, K. C. Dantrolene and “ecstasy”. Med. J. Aust. 166, 165–166 (1997).

    Article  CAS  PubMed  Google Scholar 

  43. 43

    Fidler, H., Dhillon, A., Gertner, D. & Burroughs, A. Chronic ecstasy (3,4-methylenedioxymethamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J. Hepatol. 25, 563–566 (1996).

    Article  CAS  PubMed  Google Scholar 

  44. 44

    Andreu, V. et al. Ecstasy: a common cause of severe acute hepatotoxicity. J. Hepatol. 29, 394–397 (1998).

    Article  CAS  PubMed  Google Scholar 

  45. 45

    Dykhuizen, R. S., Brunt, P. W., Atkinson, P., Simpson, J. G. & Smith, C. C. Ecstasy induced hepatitis mimicking viral hepatitis. Gut 36, 939–941 (1995).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  46. 46

    Brauer, R. B. et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transpl. Int. 10, 229–233 (1997).

    Article  CAS  PubMed  Google Scholar 

  47. 47

    Jones, A. L. & Simpson, K. J. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment. Pharmacol. Ther. 13, 129–133 (1999).

    Article  CAS  PubMed  Google Scholar 

  48. 48

    Beitia, G., Cobreros, A., Sainz, L. & Cenarruzabeitia, E. 3,4-methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: effect on cytosolic calcium signals in isolated hepatocytes. Liver 19, 234–241 (1999).

    Article  CAS  PubMed  Google Scholar 

  49. 49

    Ellis, A. J., Wendon, J. A., Portmann, B. & Williams, R. Acute liver damage and ecstasy ingestion. Gut 38, 454–458 (1996).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  50. 50

    Manchanda, S. & Connolly, M. J. Cerebral infarction in association with ecstasy abuse. Postgrad. Med. J. 69, 874–875 (1993).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  51. 51

    Suarez, R. V. & Riemersma, R. “Ecstasy” and sudden cardiac death. Am. J. Forensic Med. Pathol. 9, 339–341 (1988).

    Article  CAS  PubMed  Google Scholar 

  52. 52

    Lester, S. J. et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann. Intern. Med. 133, 969–973 (2000).

    Article  CAS  PubMed  Google Scholar 

  53. 53

    Woodrow, G., Harnden, P. & Turney, J. H. Acute renal failure due to accelerated hypertension following ingestion of 3,4-methylenedioxymethamphetamine ('ecstasy'). Nephrol. Dial. Transplant. 10, 399–400 (1995).

    CAS  PubMed  Google Scholar 

  54. 54

    Bingham, C., Beaman, M., Nicholls, A. J. & Anthony, P. P. Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy'). Nephrol. Dial. Transplant. 13, 2654–2655 (1998).

    Article  CAS  PubMed  Google Scholar 

  55. 55

    Hurault de Ligny, B. et al. Early loss of two renal grafts obtained from the same donor: role of ecstasy? Transplantation 80, 153–156 (2005).

    Article  PubMed  Google Scholar 

  56. 56

    Kwon, C., Zaritsky, A. & Dharnidharka, V. R. Transient proximal tubular renal injury following ecstasy ingestion. Pediatr. Nephrol. 18, 820–822 (2003).

    Article  PubMed  Google Scholar 

  57. 57

    Ninkovic, M. et al. Oxidative stress in rat kidneys due to 3,4-methylenedioxymetamphetamine (ecstasy) toxicity. Nephrology (Carlton) 13, 33–37 (2008).

    CAS  Google Scholar 

  58. 58

    Bryden, A. A., Rothwell, P. J. & O'Reilly, P. H. Urinary retention with misuse of “ecstasy”. BMJ 310, 504 (1995).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  59. 59

    Hill, S. L. et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin. Toxicol. (Phila.) 51, 487–492 (2013).

    Article  CAS  Google Scholar 

  60. 60

    Berney-Meyer, L., Putt, T., Schollum, J. & Walker, R. Nephrotoxicity of recreational party drugs. Nephrology (Carlton) 17, 99–103 (2012).

    Article  CAS  Google Scholar 

  61. 61

    Arbo, M. D., Bastos, M. L. & Carmo, H. F. Piperazine compounds as drugs of abuse. Drug Alcohol Depend. 122, 174–185 (2012).

    Article  CAS  PubMed  Google Scholar 

  62. 62

    Baumann, M. H. et al. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30, 550–560 (2005).

    Article  CAS  PubMed  Google Scholar 

  63. 63

    Schep, L. J., Slaughter, R. J., Vale, J. A., Beasley, D. M. & Gee, P. The clinical toxicology of the designer “party pills” benzylpiperazine and trifluoromethylphenylpiperazine. Clin. Toxicol. (Phila.) 49, 131–141 (2011).

    Article  CAS  Google Scholar 

  64. 64

    Gee, P., Richardson, S., Woltersdorf, W. & Moore, G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N. Z. Med. J. 118, U1784 (2005).

    PubMed  Google Scholar 

  65. 65

    Austin, H. & Monasterio, E. Acute psychosis following ingestion of 'Rapture'. Australas. Psychiatry 12, 406–408 (2004).

    PubMed  Google Scholar 

  66. 66

    Gee, P. & Fountain, J. Party on? BZP party pills in New Zealand. N. Z. Med. J. 120, U2422 (2007).

    PubMed  Google Scholar 

  67. 67

    Cohen, B. M. & Butler, R. BZP-party pills: a review of research on benzylpiperazine as a recreational drug. Int. J. Drug Policy 22, 95–101 (2011).

    Article  PubMed  Google Scholar 

  68. 68

    Gee, P., Jerram, T. & Bowie, D. Multiorgan failure from 1-benzylpiperazine ingestion--legal high or lethal high? Clin. Toxicol. (Phila.) 48, 230–233 (2010).

    Article  CAS  Google Scholar 

  69. 69

    Alansari, M. & Hamilton, D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N. Z. Med. J. 119, U1959 (2006).

    PubMed  Google Scholar 

  70. 70

    Miotto, K., Striebel, J., Cho, A. K. & Wang, C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 132, 1–12 (2013).

    Article  CAS  PubMed  Google Scholar 

  71. 71

    Jerry, J., Collins, G. & Streem, D. Synthetic legal intoxicating drugs: the emerging 'incense' and 'bath salt' phenomenon. Cleve. Clin. J. Med. 79, 258–264 (2012).

    Article  PubMed  Google Scholar 

  72. 72

    Vardakou, I., Pistos, C. & Spiliopoulou, C. Drugs for youth via Internet and the example of mephedrone. Toxicol. Lett. 201, 191–195 (2011).

    Article  CAS  PubMed  Google Scholar 

  73. 73

    Centers for Disease Control and Prevention. Emergency department visits after use of a drug sold as “bath salts”--Michigan, November 13, 2010–March 31, 2011. MMWR Morb. Mortal. Wkly Rep. 60, 624–627 (2011).

  74. 74

    Adebamiro, A. & Perazella, M. A. Recurrent acute kidney injury following bath salts intoxication. Am. J. Kidney Dis. 59, 273–275 (2012).

    Article  PubMed  Google Scholar 

  75. 75

    Regunath, H., Ariyamuthu, V. K., Dalal, P. & Misra, M. Bath salt intoxication causing acute kidney injury requiring hemodialysis. Hemodial. Int. 16 (Suppl. 1), S47–S49 (2012).

    Article  PubMed  Google Scholar 

  76. 76

    Borek, H. A. & Holstege, C. P. Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-methylenedioxypyrovalerone. Ann. Emerg. Med. 60, 103–105 (2012).

    Article  PubMed  Google Scholar 

  77. 77

    Seely, K. A., Lapoint, J., Moran, J. H. & Fattore, L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry 39, 234–243 (2012).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  78. 78

    Hajos, N. & Freund, T. F. Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem. Phys. Lipids 121, 73–82 (2002).

    Article  CAS  PubMed  Google Scholar 

  79. 79

    Hojo, M. et al. μ-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J. Pharmacol. Sci. 108, 308–319 (2008).

    Article  CAS  PubMed  Google Scholar 

  80. 80

    Vandrey, R., Dunn, K. E., Fry, J. A. & Girling, E. R. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 120, 238–241 (2012).

    Article  CAS  PubMed  Google Scholar 

  81. 81

    Hu, X., Primack, B. A., Barnett, T. E. & Cook, R. L. College students and use of K2: an emerging drug of abuse in young persons. Subst. Abuse Treat. Prev. Policy 6, 16 (2011).

    PubMed  PubMed Central  Article  Google Scholar 

  82. 82

    Mir, A., Obafemi, A., Young, A. & Kane, C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128, e1622–e1627 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  83. 83

    Lapoint, J. et al. Severe toxicity following synthetic cannabinoid ingestion. Clin. Toxicol. (Phila.) 49, 760–764 (2011).

    Article  CAS  Google Scholar 

  84. 84

    Bhanushali, G. K., Jain, G., Fatima, H., Leisch, L. J. & Thornley-Brown, D. AKI associated with synthetic cannabinoids: a case series. Clin. J. Am. Soc. Nephrol. 8, 523–526 (2013).

    Article  CAS  PubMed  Google Scholar 

  85. 85

    Thornton, S. L., Wood, C., Friesen, M. W. & Gerona, R. R. Synthetic cannabinoid use associated with acute kidney injury. Clin. Toxicol. (Phila.) 51, 189–190 (2013).

    Article  Google Scholar 

  86. 86

    Centers for Disease Control and Prevention. Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb. Mortal. Wkly Rep. 62, 93–98 (2013).

  87. 87

    Corazza, O., Assi, S. & Schifano, F. From “special K” to “special M”: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci. Ther. 19, 454–460 (2013).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  88. 88

    Rowland, L. M. Subanesthetic ketamine: how it alters physiology and behavior in humans. Aviat. Space Environ. Med. 76, C52–C58 (2005).

    CAS  PubMed  Google Scholar 

  89. 89

    Curran, H. V. & Morgan, C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 95, 575–590 (2000).

    Article  CAS  PubMed  Google Scholar 

  90. 90

    Garey, R. E. PCP (phencyclidine): an update. J. Psychedelic Drugs 11, 265–275 (1979).

    Article  CAS  PubMed  Google Scholar 

  91. 91

    Misselbrook, G. P. & Hamilton, E. J. Out with the old, in with the new? Case reports of the clinical features and acute management of two novel designer drugs. Acute Med. 11, 157–160 (2012).

    CAS  PubMed  Google Scholar 

  92. 92

    Kalsi, S. S., Wood, D. M. & Dargan, P. I. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg. Health Threats J. 4, 7107 (2011).

    Article  PubMed  Google Scholar 

  93. 93

    Dillon, P., Copeland, J. & Jansen, K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 69, 23–28 (2003).

    Article  PubMed  Google Scholar 

  94. 94

    Kjellgren, A. & Jonsson, K. Methoxetamine (MXE)--a phenomenological study of experiences induced by a “legal high” from the internet. J. Psychoactive Drugs 45, 276–286 (2013).

    PubMed  PubMed Central  Article  Google Scholar 

  95. 95

    Artzer, D., Patak, R. V. & Wiegmann, T. B. PCP intoxication. Management of associated renal failure. J. Kans. Med. Soc. 84, 384–385, 422 (1983).

    CAS  PubMed  Google Scholar 

  96. 96

    Barton, C. H., Sterling, M. L. & Vaziri, N. D. Rhabdomyolysis and acute renal failure associated with phencyclidine intoxication. Arch. Intern. Med. 140, 568–569 (1980).

    Article  CAS  PubMed  Google Scholar 

  97. 97

    Patel, R. & Connor, G. A review of thirty cases of rhabdomyolysis-associated acute renal failure among phencyclidine users. J. Toxicol. Clin. Toxicol. 23, 547–556 (1985).

    Article  PubMed  Google Scholar 

  98. 98

    Patel, R. Acute uric acid nephropathy: a complication of phencyclidine intoxication. Postgrad. Med. J. 58, 783–785 (1982).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  99. 99

    Tsai, T. H. et al. Ketamine-associated bladder dysfunction. Int. J. Urol. 16, 826–829 (2009).

    Article  CAS  PubMed  Google Scholar 

  100. 100

    Mason, K., Cottrell, A. M., Corrigan, A. G., Gillatt, D. A. & Mitchelmore, A. E. Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clin. Radiol. 65, 795–800 (2010).

    Article  CAS  PubMed  Google Scholar 

  101. 101

    Chu, P. S. et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int. 102, 1616–1622 (2008).

    Article  PubMed  Google Scholar 

  102. 102

    Chen, J. L. et al. Renal infarction secondary to ketamine abuse. Am. J. Emerg. Med. 31, 1153.e3–1153.e5 (2013).

    Google Scholar 

  103. 103

    Wood, D. M., Davies, S., Puchnarewicz, M., Johnston, A. & Dargan, P. I. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur. J. Clin. Pharmacol. 68, 853–856 (2012).

    Article  CAS  PubMed  Google Scholar 

  104. 104

    Waldhoer, M., Bartlett, S. E. & Whistler, J. L. Opioid receptors. Annu. Rev. Biochem. 73, 953–990 (2004).

    Article  CAS  PubMed  Google Scholar 

  105. 105

    Johnston, L. D., O'Malley, P. M., Bachman, J. G. & Schulenberg, J. E. National Institute on Drug Abuse. Monitoring the future: national survey results on drug use, 1975–2003. www.monitoringthefuture.org[online], (2014).

  106. 106

    Cicero, T. J., Inciardi, J. A. & Munoz, A. Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002–2004. J. Pain 6, 662–672 (2005).

    Article  PubMed  Google Scholar 

  107. 107

    Jaffe, J. A. & Kimmel, P. L. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin. J. Am. Soc. Nephrol. 1, 655–667 (2006).

    Article  CAS  PubMed  Google Scholar 

  108. 108

    Centers for Disease Control and Prevention. Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012. MMWR Morb. Mortal. Wkly Rep. 62, 1–4 (2013).

Download references

Author information

Affiliations

Authors

Contributions

R.L.L. and M.A.P. researched the data for the article, provided substantial contributions to discussions of its content, wrote the article and undertook review and/or editing of the manuscript before submission.

Corresponding author

Correspondence to Mark A. Perazella.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Luciano, R., Perazella, M. Nephrotoxic effects of designer drugs: synthetic is not better!. Nat Rev Nephrol 10, 314–324 (2014). https://doi.org/10.1038/nrneph.2014.44

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing